Latest news with #forQuotations
India Gazette
8 hours ago
- Business
- India Gazette
China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs
New Delhi [India], June 25 (ANI): Indian pharmaceutical and biotech sectors have started witnessing tangible benefits from the global shift away from China, as early signs of the China+1 strategy materialising emerge, according to a recent Goldman Sachs report. Some pharmaceutical and biotech companies report that they have started witnessing the conversion of earlier enquiries and Requests for Quotations (RFQs) into pilot projects and small contracts. The 'China Plus One' strategy is a business technique in which corporations diversify their manufacturing and supply chains by expanding into countries other than China while still keeping a presence in China. The report was prepared based on the outcome of the '2nd annual India CRO/CDMO trip' event in Bangalore and Hyderabad. The credit rating firm, in its equity report, added that Indian companies witnessed a major uptick in RFQs from global clients looking to diversify supply chains away from China. While these developments indicate progress, the report also noted that large-scale financial gains from these shifts will take time, possibly a three- to five-years. 'After seeing a significant influx of enquiries/ RFQs over the past 1-1.5 years, management of some companies like Syngene, Neuland, Divi's, etc. have now started highlighting instances of conversion of RFQs to pilot projects/contracts, although large financial benefits will still take time to materialise,' the report added. The report further added, 'We expect the geographic supply chain diversification theme to play out over a 3-5 year period, if not more.' The report also speaks about BIOSECURE Act of the United States, an evolving policy which directs to reduce American dependence on Chinese biotech suppliers. 'While investor discussion around the BIOSECURE Act is relatively light as there have been limited updates on this topic, most corporates acknowledged that their clients are actively building strategies to reduce their dependence on China,' Goldman Sachs added in the report. Interestingly, the report observes that this trend is being led by large pharmaceutical and biotech companies, which are more willing and able to bear the switching costs involved. Contrary to the big players, smaller companies, in the US and Europe, are still hesitant due to funding constraints and the capital-intensive nature of moving suppliers. While there is little immediate investor focus on the act due to limited updates, corporates across the sector confirmed that their clients are proactively preparing for a post-China sourcing strategy. (ANI)
Mint
9 hours ago
- Business
- Mint
China 1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs
New Delhi [India], : Indian pharmaceutical and biotech sectors have started witnessing tangible benefits from the global shift away from China, as early signs of the China 1 strategy materialising emerge, according to a recent Goldman Sachs report. Some pharmaceutical and biotech companies report that they have started witnessing the conversion of earlier enquiries and Requests for Quotations into pilot projects and small contracts. The 'China Plus One' strategy is a business technique in which corporations diversify their manufacturing and supply chains by expanding into countries other than China while still keeping a presence in China. The report was prepared based on the outcome of the '2nd annual India CRO/CDMO trip' event in Bengaluru and Hyderabad. The credit rating firm, in its equity report, added that Indian companies witnessed a major uptick in RFQs from global clients looking to diversify supply chains away from China. While these developments indicate progress, the report also noted that large-scale financial gains from these shifts will take time, possibly a three- to five-years. "After seeing a significant influx of enquiries/ RFQs over the past 1-1.5 years, management of some companies like Syngene, Neuland, Divi's, etc. have now started highlighting instances of conversion of RFQs to pilot projects/contracts, although large financial benefits will still take time to materialise," the report added. The report further added, "We expect the geographic supply chain diversification theme to play out over a 3-5 year period, if not more." The report also speaks about BIOSECURE Act of the United States, an evolving policy which directs to reduce American dependence on Chinese biotech suppliers. "While investor discussion around the BIOSECURE Act is relatively light as there have been limited updates on this topic, most corporates acknowledged that their clients are actively building strategies to reduce their dependence on China," Goldman Sachs added in the report. Interestingly, the report observes that this trend is being led by large pharmaceutical and biotech companies, which are more willing and able to bear the switching costs involved. Contrary to the big players, smaller companies, in the US and Europe, are still hesitant due to funding constraints and the capital-intensive nature of moving suppliers. While there is little immediate investor focus on the act due to limited updates, corporates across the sector confirmed that their clients are proactively preparing for a post-China sourcing strategy.
Time of India
11 hours ago
- Business
- Time of India
China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs
Indian pharmaceutical and biotech sectors have started witnessing tangible benefits from the global shift away from China , as early signs of the China+1 strategy materialising emerge, according to a recent Goldman Sachs report . Some pharmaceutical and biotech companies report that they have started witnessing the conversion of earlier enquiries and Requests for Quotations (RFQs) into pilot projects and small contracts. The 'China Plus One' strategy is a business technique in which corporations diversify their manufacturing and supply chains by expanding into countries other than China while still keeping a presence in China. The report was prepared based on the outcome of the '2nd annual India CRO/CDMO trip' event in Bangalore and Hyderabad. The credit rating firm, in its equity report, added that Indian companies witnessed a major uptick in RFQs from global clients looking to diversify supply chains away from China. Live Events While these developments indicate progress, the report also noted that large-scale financial gains from these shifts will take time, possibly a three- to five-years. "After seeing a significant influx of enquiries/ RFQs over the past 1-1.5 years, management of some companies like Syngene, Neuland, Divi's , etc. have now started highlighting instances of conversion of RFQs to pilot projects/contracts, although large financial benefits will still take time to materialise," the report added. The report further added, "We expect the geographic supply chain diversification theme to play out over a 3-5 year period, if not more." The report also speaks about BIOSECURE Act of the United States , an evolving policy which directs to reduce American dependence on Chinese biotech suppliers. "While investor discussion around the BIOSECURE Act is relatively light as there have been limited updates on this topic, most corporates acknowledged that their clients are actively building strategies to reduce their dependence on China," Goldman Sachs added in the report. Interestingly, the report observes that this trend is being led by large pharmaceutical and biotech companies, which are more willing and able to bear the switching costs involved. Contrary to the big players, smaller companies, in the US and Europe, are still hesitant due to funding constraints and the capital-intensive nature of moving suppliers. While there is little immediate investor focus on the act due to limited updates, corporates across the sector confirmed that their clients are proactively preparing for a post-China sourcing strategy.
Yahoo
19 hours ago
- Business
- Yahoo
Is WidePoint Positioned to Capitalize on Spiral 4 Contract Activity?
WidePoint Corporation WYY is making visible progress under the Department of Defense's Spiral 4 contract, positioning it for long-term execution gains. This contract, valued at up to $2.7 billion across multiple vendors, represents a major pipeline opportunity. The opportunity is especially timely as many task orders under the previous Spiral 3 vehicle are approaching the first quarter of 2025, WidePoint secured two new task orders under Spiral 4, adding to a base-year award announced earlier, which holds a potential 10-year value of roughly $25 million. While the latest awards were modest in size, management noted that increased activity and incoming Requests for Quotations ('RFQ') are signs of growing traction. Several awards under Spiral 3 are set to end by mid-2025 and WidePoint expects momentum to pick up as agencies transition contracts to the new support this growth, the company is expanding its internal team dedicated to Spiral 4, indicating confidence in both pipeline conversion and long-term execution. Unlike most competitors on the vehicle, WidePoint delivers managed mobility and lifecycle services that go beyond core carrier offerings — a point it believes strengthens more RFQs in motion and an active shift from Spiral 3 to Spiral 4, WidePoint appears focused on capturing recurring task orders under this large-scale federal contract. The coming quarters will be key in determining whether early progress can translate into sustainable growth across its federal portfolio. While WidePoint is steadily gaining ground under Spiral 4, other federal mobility providers are also making moves under the same contract. Among them, EchoStar Corporation SATS and T-Mobile US, Inc. TMUS have emerged as key players positioning themselves within this through its subsidiary Hughes Network Systems, is leveraging Spiral 4 to expand the role in federal mobility by offering integrated 5G and satellite-backed connectivity solutions. The company's focus remains on delivering secure, wide-area coverage for mission-critical use cases, especially in remote or infrastructure-limited environments. However, ongoing operational scrutiny around its wireless service obligations could pose challenges as EchoStar scales within the federal space.T-Mobile is also participating in Spiral 4, bringing its nationwide 5G network and secure mobility offerings to the federal market. On June 13, 2024, the company was selected by the U.S. Department of the Navy as a wireless solutions provider under the $2.67 billion contract. The award enables Department of Defense agencies to procure wireless services and equipment from T-Mobile for the next 10 years. Through Spiral 4, the company is offering voice, data, fixed wireless, IoT and mobility management services, all supported by its national 5G network. T-Mobile continues to build on its product portfolio and track record in government, aiming to serve both military and civilian agencies with scalable, secure solutions. WYY's shares have declined 14.6% in the past three months against the industry's rise of 8.4%. Image Source: Zacks Investment Research WYY stock is currently trading at a discount. It is currently trading at a forward 12-month price-to-sales multiple of 0.18X, well below the industry average of 1.8X, reflecting an attractive investment opportunity. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 has shifted from earnings of 1 cent per share to a loss of 14 cents over the past 60 days. WYY's earnings for 2026 are likely to witness robust growth of 175%. Image Source: Zacks Investment Research The company currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report WidePoint Corporation (WYY) : Free Stock Analysis Report EchoStar Corporation (SATS) : Free Stock Analysis Report T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
